FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	D.C. 20549
---------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Nolan Garry Ph.D.					2. Issuer Name and Ticker or Trading Symbol Akoya Biosciences, Inc. [AKYA]										all applicable) Director		ng Person(s) to Issuer		
(Last)	(Fir	rst) (N VE,6TH FLOOR	Middl	le)	3. Date of Earliest Transaction (Month/Day/Year) 09/09/2022									belov			Other (s		
(Street) MARLBOROUGH MA 01762 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table	1-1	Non-Deriva	tive	Secui	rities	Ac	quir	ed, D	isposed c	f, or I	3enefi	cially	Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					ar) Execution				3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			nd 5) Secu Bene		cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code	v	Amount	mount (A) or Brice		Transa	Transaction(s) (Instr. 3 and 4)		4)	(5 4)				
Common Stock				09/09/202	!2				S	П	22,191	D	\$13.30)89 ⁽¹⁾	63	632,893		D	
Common Stock 09/1				09/12/202	22				S	1,800		D	\$13.3023(2)		(2) 631,093			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rative Conversion Date Execution D rity or Exercise (Month/Day/Year) if any					5. Numb of Derivativ Securitie Acquirer (A) or Dispose of (D) (Instr. 3, and 5)		ative rities ired sed	Expiration (Month/Dates d			Amo Secu Unde Deriv	le and unt of rities erlying rative rity (Instr i 4)	Deri Sec (Ins	rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exe	e ercisable	Expiration Date	Title	Amoun or Numbe of Shares	r					

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.25 to \$13.445, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.25 to \$13.36, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.

/s/ Garry Nolan, by Brian McKelligon, as Attorney-in-

Fact

** Signature of Reporting Person Date

09/13/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.